{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:11:14Z","timestamp":1761174674994,"version":"build-2065373602"},"reference-count":39,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2002,12,1]],"date-time":"2002-12-01T00:00:00Z","timestamp":1038700800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":4382,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2002,12]]},"DOI":"10.1046\/j.1469-0691.2002.00484.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T07:26:51Z","timestamp":1047367611000},"page":"791-800","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"title":["Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox\u00ae antimicrobial potency study (ZAPS-Europe)"],"prefix":"10.1016","volume":"8","author":[{"given":"A.","family":"Bolmstrom","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.H.","family":"Ballow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Qwarnstrom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.J.","family":"Biedenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1046\/j.1469-0691.2002.00484.x_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2165\/00003495-199600511-00004","article-title":"Emerging resistance to antimicrobial agents in Gram-positive bacterial: Enterococci, staphylococci and non-pneumococcal streptococci","volume":"51","author":"Cormican","year":"1996","journal-title":"Drugs"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib2","doi-asserted-by":"crossref","first-page":"3S","DOI":"10.1016\/S0002-9343(96)00102-7","article-title":"Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients","volume":"100","author":"Jones","year":"1996","journal-title":"Am J Med"},{"issue":"Suppl. A","key":"10.1046\/j.1469-0691.2002.00484.x_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/39.suppl_1.1","article-title":"Gram-positive resistance: Challenge for the development of new antibiotics","volume":"39","author":"Baquero","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1021\/jm9509556","article-title":"Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant Gram-positive bacterial infections","volume":"39","author":"Brickner","year":"1996","journal-title":"J Med Chem"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib5","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0732-8893(00)00124-3","article-title":"Antimicrobial activity of advanced-spectrum fluoroquinolones tested against more than 2000 contemporary bacterial isolates of species causing community-acquired respiratory tract infections in the United States 1999","volume":"37","author":"Deshpande","year":"2000","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib6","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S0732-8893(98)80002-3","article-title":"Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid\u00ae) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada","volume":"30","author":"Jones","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib7","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/jac\/47.1.15","article-title":"In vitro Gram-positive antimicrobial activity of evernimicin (SHC 27899), a novel oligosaccharide, compared with other antimicrobials: a multicentre international trial","volume":"47","author":"Jones","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib8","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2165\/00003495-200059010-00002","article-title":"Oxazolidinones: a review","volume":"59","author":"Diekema","year":"2000","journal-title":"Drugs"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib9","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1128\/AAC.40.4.839","article-title":"In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents","volume":"40","author":"Zurenko","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib10","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1517\/13543784.8.8.1195","article-title":"Mechanism of action of the oxazolidinone antibacterial agents","volume":"8","author":"Shinabarger","year":"1999","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib11","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1128\/AAC.40.3.720","article-title":"In vitro antimicrobial activities and spectra of U-100592 and U-100766, two novel fluorinated oxazolidinones","volume":"40","author":"Jones","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib14","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1128\/AAC.40.4.1039","article-title":"In vitro activities of oxazolidinones U-100592 and U-100766 against penicillin-resistant and cephalosporin-resistant strains of Streptococcus pneumoniae","volume":"40","author":"Mason","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib15","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against Staphylococci and Enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib16","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1093\/jac\/48.1.47","article-title":"Susceptibility of a variety of clinical isolates to linezolid: a European inter-country comparison","volume":"48","author":"Gemmell","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib17","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0732-8893(01)00235-8","article-title":"Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox\u00ae antimicrobial potency study (ZAPS) in the United States","volume":"40","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib18","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1046\/j.1198-743x.2001.00305.x","article-title":"The DUEL study: a multicenter in vitro evaluation of linezolid compared with other antibiotics in the Netherlands","volume":"7","author":"Mouton","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib19","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1046\/j.1198-743x.2001.00239.x","article-title":"Surveillance of antimicrobial resistance. What, how and whither?","volume":"7","author":"Bax","year":"2001","journal-title":"Clin Microbiol Infect"},{"issue":"Suppl. 2","key":"10.1046\/j.1469-0691.2002.00484.x_bib20","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1086\/320184","volume":"32","author":"Diekema","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"2","key":"10.1046\/j.1469-0691.2002.00484.x_bib21","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1086\/520192","article-title":"Nosocomial bloodstream infections in United States hospitals: a three-year analysis","volume":"29","author":"Edmond","year":"1999","journal-title":"Clin Infect Dis"},{"issue":"Suppl. 2","key":"10.1046\/j.1469-0691.2002.00484.x_bib22","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Hoban","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib23","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0732-8893(98)00149-7","article-title":"Survey of blood stream infections attributable to Gram-positive cocci: Frequency of occurrence and antimicrobial susceptibility of isolates collected in 1997 in the United States, Canada, and Latin America from the SENTRY Antimicrobial Surveillance Program","volume":"33","author":"Pfaller","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib24","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1086\/317542","article-title":"Vancomycin-intermediate and -resistant Staphylococcus aureus: What the infectious disease specialist needs to know","volume":"32","author":"Fridkin","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib25","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJM199907223410403","article-title":"Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada","volume":"341","author":"Chen","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199958010-00001","article-title":"Penicillin- and cephalosporin-resistant Streptococcus pneumoniae. Emerging treatment for an emerging problem","volume":"58","author":"Klugman","year":"1999","journal-title":"Drugs"},{"year":"2002","series-title":"Performance standard for antimicrobial susceptibility testing","key":"10.1046\/j.1469-0691.2002.00484.x_bib27"},{"year":"2000","series-title":"Performance standards for antimicrobial disk susceptibility tests","key":"10.1046\/j.1469-0691.2002.00484.x_bib28"},{"year":"2000","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","key":"10.1046\/j.1469-0691.2002.00484.x_bib29"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib30","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/jac\/47.5.675","article-title":"In vitro activity of linezolid and 11 other antimicrobials against 566 clinical isolates and comparison between NCCLS microdilution and Etest methods","volume":"47","author":"Taubau","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib31","first-page":"284","article-title":"EUCAST definitive document E. Def 4.1: Linezolid breakpoints","volume":"7","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib32","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0732-8893(99)00032-2","article-title":"Practical approach to the identification of clinically relevant Enterococcus species","volume":"34","author":"Willey","year":"1999","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1093\/clinids\/24.1.90","article-title":"Emergence of increased resistance to quinupristin\/dalfopristin during therapy for Enterococcus faecium bacteremia","volume":"24","author":"Chow","year":"1997","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib34","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1086\/313710","article-title":"Antimicrobial susceptibility and frequency of occurrence of clinical blood isolates in Europe from the SENTRY Antimicrobial Surveillance Program 1997 and 1998","volume":"30","author":"Fluit","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib35","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1128\/JCM.39.7.2439-2444.2001","article-title":"Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides","volume":"39","author":"Walsh","year":"2001","journal-title":"J Clin Microbiol"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib36","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3201\/eid0702.010237","article-title":"Increasing resistance to vancomycin and other glycopeptides in Staphylococcus aureus","volume":"7","author":"Tenover","year":"2001","journal-title":"Emerging Infect Dis"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib37","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/S0140-6736(00)04376-2","article-title":"Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid","volume":"357","author":"Gonzales","year":"2001","journal-title":"Lancet"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"The Lancet"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib39","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1093\/jac\/46.6.931","article-title":"Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid","volume":"46","author":"Henwood","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib12","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1128\/AAC.41.2.465","article-title":"In vitro activities of the oxazolidinone antibiotics U-100592 and U-100766 against Staphylococcus aureus and coagulase-negative Staphylococcus species","volume":"41","author":"Jorgensen","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1046\/j.1469-0691.2002.00484.x_bib13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM198807213190307","article-title":"Plasma-mediated resistance to vancomycin and teicoplanin in Enterococcus faecium","volume":"319","author":"Leclercq","year":"1988","journal-title":"N Engl J Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14625222?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14625222?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:16:01Z","timestamp":1761117361000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14625222"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12]]},"references-count":39,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2002,12]]}},"alternative-id":["S1198743X14625222"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2002.00484.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2002,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multicentre assessment of linezolid antimicrobial activity and spectrum in Europe: report from the Zyvox\u00ae antimicrobial potency study (ZAPS-Europe)","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1469-0691.2002.00484.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2002 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}